Alcon Reports Results for Dry-Eye-Treatment Trials
10 1월 2024 - 7:20AM
Dow Jones News
By Denny Jacob
Alcon reported topline results from two trials evaluating
AR-15512, a candidate treatment for dry-eye disease.
The eye-care company said the primary endpoint achieved
statistical significance in both trials. Additional data derived
from secondary endpoints demonstrated the rapid onset and sustained
tear production, said Alcon.
AR-15512 was well tolerated and no serious ocular adverse events
were reported.
Alcon expects to file a new drug application for AR-15512 with
the U.S. Food and Drug Administration in mid-2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 09, 2024 17:05 ET (22:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Alcon (NYSE:ALC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Alcon (NYSE:ALC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
